

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Smith, CJ;Heal, C;Vail, A;Jeans, AR;Westendorp, WF;Nederkoorn, PJ;Van De Beek, D;Kalra, L;Montaner, J;Woodhead, M;Meisel, A;Lees, KR;Alexandrov, A;Bath, PM;Berge, E;Bluhmki, E;Bornstein, N;Chen, C;Claesson, L;Davis, SM;Donnan, G;Diener, HC;Fisher, M;Ginsberg, M;Gregson, B;Grotta, J;Hacke, W;Hennerici, MG;Hommel, M;Kaste, M;Lyden, P;Marler, J;Muir, K;Venketasubramanian, N;Sacco, R;Shuaib, A;Teal, P;Wahlgren, NG;Warach, S;Weimar, C

Title:

Antibiotic Class and Outcome in Post-stroke Infections: An individual participant data pooled analysis of VISTA-acute

Date:

2019-01-01

Citation:

Smith, C. J., Heal, C., Vail, A., Jeans, A. R., Westendorp, W. F., Nederkoorn, P. J., Van De Beek, D., Kalra, L., Montaner, J., Woodhead, M., Meisel, A., Lees, K. R., Alexandrov, A., Bath, P. M., Berge, E., Bluhmki, E., Bornstein, N., Chen, C., Claesson, L. ,... Weimar, C. (2019). Antibiotic Class and Outcome in Post-stroke Infections: An individual participant data pooled analysis of VISTA-acute. *Frontiers in Neurology*, 10 (MAY), <https://doi.org/10.3389/fneur.2019.00504>.

Persistent Link:

<https://hdl.handle.net/11343/271521>

License:

CC BY



Antibiotic Class and Outcome in Post-stroke Infections: An Individual Participant Data Pooled Analysis of VISTA-Acute

Craig J. Smith^{1,2}, Calvin Heal³, Andy Vail³, Adam R. Jeans⁴, Willeke F. Westendorp⁵, Paul J. Nederkoorn⁵, Diederik van de Beek⁵, Lalit Kalra⁶, Joan Montaner^{7,8}, Mark Woodhead⁹, and Andreas Meisel^{10*} on behalf of the VISTA Collaboration and PISCES Group

¹ Greater Manchester Comprehensive Stroke Centre, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, United Kingdom, ² Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, ³ Centre for Biostatistics, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁴ Division of Clinical Support Services and Tertiary Medicine, Department of Microbiology, Salford Royal NHS Foundation Trust, Salford, United Kingdom, ⁵ Department of Neurology, Amsterdam Neuroscience, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶ Clinical Neurosciences, King's College Hospital NHS Foundation Trust London, London, United Kingdom, ⁷ Neurovascular Research Laboratory, Vall d' Hebron Institute of Research, Barcelona, Spain, ⁸ Stroke Research Program, Department of Neurology, Institute de Biomedicine of Seville, Hospital Universitario Virgen Macarena, IBI/Hospital Universitario Virgen del Rocío/CSIC/University of Seville, Seville, Spain, ⁹ Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ¹⁰ Department of Neurology, NeuroCure Clinical Research Center, Center for Stroke Research Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany

OPEN ACCESS

Edited by:

Thanh G. Phan,
Monash Health, Australia

Reviewed by:

Terence J. Quinn,
University of Glasgow,
United Kingdom
Velandai Srikanth,
Monash University, Australia

*Correspondence:

Andreas Meisel
andreas.meisel@charite.de

Specialty section:

This article was submitted to
Stroke,
a section of the journal
Frontiers in Neurology

Received: 27 February 2019

Accepted: 26 April 2019

Published: 14 May 2019

Citation:

Smith CJ, Heal C, Vail A, Jeans AR, Westendorp WF, Nederkoorn PJ, van de Beek D, Kalra L, Montaner J, Woodhead M and Meisel A (2019) Antibiotic Class and Outcome in Post-stroke Infections: An Individual Participant Data Pooled Analysis of VISTA-Acute. *Front. Neurol.* 10:504. doi: 10.3389/fneur.2019.00504

Introduction: Antibiotics used to treat post-stroke infections have differing antimicrobial and anti-inflammatory effects. Our aim was to investigate whether antibiotic class was associated with outcome after post-stroke infection.

Methods: We analyzed pooled individual participant data from the Virtual International Stroke Trials Archive (VISTA)-Acute. Patients with ischemic stroke and with an infection treated with systemic antibiotic therapy during the first 2 weeks after stroke onset were eligible. Antibiotics were grouped into eight classes, according to antimicrobial mechanism and prevalence. The primary analysis investigated whether antibiotic class for any infection, or for pneumonia, was independently associated with a shift in 90 day modified Rankin Scale (mRS) using ordinal logistic regression.

Results: 2,708 patients were eligible (median age [IQR] = 74 [65 to 80] y; 51% female; median [IQR] NIHSS score = 15 [11 to 19]). Pneumonia occurred in 35%. Treatment with macrolides (5% of any infections; 9% of pneumonias) was independently associated with more favorable mRS distribution for any infection [OR (95% CI) = 0.59 (0.42 to 0.83), $p = 0.004$] and for pneumonia [OR (95% CI) = 0.46 (0.29 to 0.73), $p = 0.001$]. Unfavorable mRS distribution was independently associated with treatment of any infection either with carbapenems, cephalosporins or monobactams [OR (95% CI) = 1.62 (1.33 to 1.97), $p < 0.001$], penicillin plus β -lactamase inhibitors [OR (95% CI) = 1.26 (1.03 to 1.54), $p = 0.025$] or with aminoglycosides [OR (95% CI) = 1.73 (1.22 to 2.46), $p = 0.002$].

Conclusion: This retrospective study has several limitations including effect modification and confounding by indication. Macrolides may have favorable immune-modulatory effects in stroke-associated infections. Prospective evaluation of the impact of antibiotic class on treatment of post-stroke infections is warranted.

Keywords: stroke, acute, post-stroke infections, post-stroke pneumonia, antibiotics, prognosis

INTRODUCTION

Infections frequently complicate stroke, occurring in up to 30% of patients, and increase the likelihood of death and unfavorable outcomes in survivors (1–3). Whilst antibiotics are the mainstay of treatment, the microbiological etiology of common infections complicating stroke, such as pneumonia or urinary tract infection, are poorly characterized. Further, there are no antibiotic treatment trials of infections complicating stroke. The effectiveness of different antibiotic classes is therefore uncertain, there is a lack of evidence to inform antibiotic guidelines (e.g., for pneumonia complicating stroke) and empirical antibiotic treatment is variable (4, 5).

Inflammatory and immune responses play a central role in the pathophysiology of stroke and associated clinical outcomes (6). Post-stroke infections exacerbate deleterious inflammatory and immune responses, which may impact further on adverse outcomes (7). Antibiotics used to treat post-stroke infections can modulate the pathophysiology of experimental stroke independent of their anti-microbial effects, by modulating inflammatory or excitotoxic pathways (8–14). Randomized trials of prophylactic antibiotics in acute stroke have failed to improve clinical outcomes or prevent pneumonia (3, 5, 15–17), and had varying effects in preventing urinary tract infections. This has raised questions about the potential effectiveness of some antibiotic classes commonly used for post-stroke infections, particularly pneumonia (18).

Taken together, these data suggest that choice of antibiotic class for post-stroke infections could have important implications for clinical outcomes. We therefore hypothesized that antibiotic class influences outcome after stroke relating to spectrum of antimicrobial coverage and to other (e.g., inflammatory) mechanisms independent of antimicrobial effects. The aim of this study was to investigate whether class of antibiotic used to treat clinically diagnosed pneumonia or any infection in the first 2 weeks after stroke was associated with clinical outcomes.

PATIENTS AND METHODS

We undertook a retrospective pooled analysis of individual participant data from the Virtual International Stroke Trials Archive (VISTA)-Acute (www.virtualtrialsarchives.org/vista). The study protocol was approved by the VISTA-Acute Steering Committee. Dedicated ethical approval was not required as anonymized historical patient data were being used. The VISTA-Acute repository was screened by the VISTA

coordinator for eligible acute ischemic stroke randomized controlled trials (RCTs) meeting the following study-level criteria: (i) Adverse Event (AE) and Serious Adverse Event (SAE) data recorded during the first 2 weeks after enrolment which included post-stroke infections, including both type of infection and name of antibiotic therapy; (ii) 90 day clinical outcomes: modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI); (iii) core demographic variables (including age, sex, country where randomized, year of study, vascular risk profile and smoking history) and clinical variables (baseline NIHSS, baseline mRS pre-stroke, concurrent medications, baseline glucose concentration). For the eligible RCTs identified, individual participant data for trial participants with an infection recorded and treated within the first 2 weeks after stroke onset were anonymized and extracted. Individual participant SAE and AE data were reviewed by a single researcher (CJS) to classify infection sub-type and categorize systemic antibiotic treatment by class, blinded to the baseline characteristics and clinical outcomes.

Infection Category

Categorization of the infections into sub-types was based on review of the information recorded in the reported SAEs and AEs, and was therefore necessarily both pragmatic and also reflective of usual clinical practice. Infections were categorized as follows: (i) Pneumonia (including description or coding of pneumonia, aspiration pneumonia, inhalation pneumonia, chest infection, lung consolidation, bronchopulmonary infection, bronchial infection); (ii) Tracheobronchitis (including acute bronchitis, acute exacerbation of bronchitis, acute tracheobronchitis, upper respiratory tract infection, exacerbation of chronic airways disease/obstructive pulmonary disease or asthma); (iii) Urogenital infections (including urinary tract infection, pyelonephritis, cystitis, prostatitis, vaginal infection); (iv) Other defined infections (skin and soft tissue, dental, joint, gastrointestinal, meningitis/ ventriculitis, pharyngeal/throat, and ear) requiring systemic antibiotics. The majority of these were self-explanatory based on reported diagnosis (e.g., aspiration pneumonia, acute bronchopneumonia, hospital-acquired pneumonia; acute tracheobronchitis, exacerbation of chronic bronchitis; acute pyelonephritis, urinary tract infection) or description (e.g., “yellow secretions, basilar crackle + scattered rhonchi”; “infection intravenous cannula site”). A final category, (v) Uncertain source of infection, was included for when there was sufficient clinical suspicion of infection to initiate systemic antibiotics but without a definite source of infection

reported or where the site of infection could not be concluded from the available information. Patients were excluded if they received preventative antibiotics; had an identified infection but received no systemic antibiotic treatment, received treatment for an infection caused by proven or suspected *Candida* spp or *Mycobacterial* spp. Uncertainties relating to the site of infection or any other aspect of categorization into sub-type were resolved by discussion with the study microbiologist (ARJ).

Antibiotic Class

All recorded antibiotics were individually reviewed by a single researcher (CJS). Antibiotics with systemic (oral, via enteral tube, intravenous or intramuscular) administration were grouped, prior to consideration of their association with outcomes, as follows based on mechanism of action (Table 1) and prevalence in the final cohort: (i) lincosamides and tetracyclines; (ii) cephalosporins, carbapenems, and monobactams; (iii) aminoglycosides; (iv) fluoroquinolones; (v) penicillins; (vi) penicillin plus β-lactamase inhibitor; (vii) other (sulphonamides, folic acid inhibitors, metronidazole, nitrofurans, and glycopeptides); (viii) macrolides.

Statistical Analyses

The exposure of interest was antibiotic class used to treat post-stroke infection during the first 2 weeks after ischemic stroke onset. The primary outcome measure was the 7-point mRS score at 90 days (incorporating death as score 6). Secondary outcomes included NIHSS and BI at 90 days. Baseline characteristics were summarized for pooled study data. To determine whether antibiotic class, or other prognostic variables were associated with the primary outcome, we performed multifactorial ordinal logistic regression to obtain an adjusted odds ratio with 95% confidence interval (CI) for a shift in mRS. Antibiotic class and infection subtype were each entered into the model as categorical predictor variables, allowing us to account for subsequent infections and multiple different antibiotic exposures in the analysis. Other potential confounding individual-level and study-level characteristics were also included as independent variables and included age, sex, year, geographical region/continent, baseline NIHSS, categorical infection subtype, thrombolysis treatment, and prior statin treatment. We included statins as they are independently associated with outcome after stroke (19) and are implicated in both the risk of stroke-associated infections and prognosis (20–23). Data restrictions prevented direct inclusion of a trial identifier in the analyses. In the primary analysis we investigated the independent association between antibiotic class and 90 day mRS both for any infection and also for pneumonia separately. Secondary analyses of 90 day BI and NIHSS incorporated deceased patients, and used ordinal logistic regression undertaken for any infection and also pneumonia separately, adjusted for the same independent variables.

TABLE 1 | Antibiotics and spectrum of activity.

	Staphylococcus aureus, MSSA	Staphylococcus aureus, MRSA	Streptococcus pneumoniae	Enterococci	Coliforms	Coliforms, ESBL	Haemophilus influenzae	Pseudomonas	Acinetobacter	Anaerobes (Gram positive)	Anaerobes (Gram negative)	Mycoplasma	Site of action
Aminoglycosides	+		0	0	+	+	0	+	+	0	0	0	Ribosome
Carbapenems	++	0	++	0	++	++	++	+	+	+	++	0	Cell wall
Cephalosporins (3 rd generation)	+	0	++	0	±	0	++	+	±	+	0	0	Cell wall
Fluoroquinolones	+	±	±	±	+	+	++	+	+	0	0	+	Nucleic acid
Glycopeptides	+	+	+	+	0	0	0	0	0	±	0	0	Cell wall
Lincosamides	+	±	±	0	0	0	±	0	0	±	±	0	Ribosome
Macrolides	+	±	±	0	0	0	±	0	0	±	±	0	Ribosome
Metronidazole	0	0	0	0	0	0	0	0	0	±	±	0	Nucleic acid
Monobactams	0	0	0	0	+	0	+	+	0	0	0	0	Cell wall
Nitrofurans	0	0	0	+	+	+	+	0	0	0	0	0	Nucleic acid
Penicillins	++	0	+	±	±	+	±	0	0	+	0	0	Cell wall
Penicillin plus β-lactamase inhibitors	+	0	+	±	+	±	+	+	±	++	++	0	Cell wall
Sulphonamides/folic acid inhibitors	+	+	±	±	+	+	+	0	±	0	0	0	Folate synthesis
Tetracyclines	+	+	±	0	±	±	+	0	±	+	±	+	Ribosome

Where activity varies within an antibiotic group, the most active commercially available agent is assumed. 0, Limited usefulness as monotherapy; ±, Variable activity. Efficacy often limited by resistance; +, Active. Likely to be clinically effective, but resistance may occur; ++, Highly active. Agent highly potent and resistance unusual.

Sample Size

A preliminary screen of individual participant data for >30 RCTS in VISTA-Acute led us to anticipate inclusion of >2,000 participants meeting the eligibility criteria. We anticipated that statistical power would depend critically on the distribution of antibiotic classes used, and that of the mRS within patients treated for infection. Analysis on the ordinal scale, assuming the proportional odds assumption holds in eligible patients, as it would be anticipated to do in unselected patients, would increase power over a binary outcome analysis. For illustrative purposes, a simple power calculation on the binary scale indicated that a comparison of 600 patients treated with each of two classes of antibiotics would provide 80% power to detect an odds ratio of 1.5 from a baseline of 75% with “good outcome.”

RESULTS

2,708 patients were eligible with a total of 3,081 infections treated with systemic antibiotics during the first 2 weeks after

stroke onset (any infection). Pneumonia occurred in 35%, and urogenital infections in 42% of the participants. Trials between 1998 and 2013 were represented, which included participating centers from Europe, Asia, Africa, Australasia and the Americas. The baseline characteristics and clinical outcomes for the final sample (median age [IQR] = 74 [65 to 80] y; 51% female; median [IQR] NIHSS score = 15 [11 to 19]; 90 day case fatality 26%) and the different infection categories are presented in **Table 2**. The baseline characteristics and clinical outcomes for patients receiving the different antibiotic classes in any infection and pneumonia are presented in **Tables 3, 4**.

The prevalence of the antibiotic classes in the different infection categories is shown in **Table 5**. Antibiotic dosage, duration and route of administration were not available. **Table 6** shows the frequency of prescription of monotherapy with one antibiotic agent, or combination treatment with >1 antibiotic agent, for the infection categories. Combination therapy with >1 antibiotic agents occurred most often in pneumonia, with at least two antibiotics prescribed in 42% of cases compared with 20%

TABLE 2 | Baseline characteristics and 90 day clinical outcomes according to infection category.

Number of infections	Any infection 3081	Pneumonia 958	Tracheobronchitis 170	Urogenital infection 1132	Other infection 330	Uncertain infection 491
Number of patients	2708	958	170	1132	330	490
Median (IQR) age (y)	74 (65 to 80)	74 (66 to 80)	72 (65 to 78)	74 (66 to 80)	73 (64 to 80)	73 (65 to 79)
Female sex, <i>n</i> (%)	1372 (51%)	387 (40%)	67 (39%)	727 (64%)	140 (42%)	225 (46%)
Median (IQR) NIHSS	15 (11 to 19)	16 (12 to 20)	13 (9 to 17)	14 (11 to 18)	14 (10 to 17)	16 (12 to 20)
Median (IQR) time to first infection (d)	5 (3 to 9)	4 (2 to 7)	3 (2 to 7)	6 (3 to 14)	6 (3 to 21)	4 (2 to 6)
IV thrombolysis, <i>n</i> (%)	795 (26%)	270 (28%)	44 (26%)	282 (25%)	75 (23%)	124 (25%)
Mean (SD) pre-stroke mRS	1.2 (0.6)	1.2 (0.6)	1.1 (0.3)	1.3 (0.7)	1.3 (0.8)	1.2 (0.5)
Median (IQR) glucose concentration (mmol/L)	6.9 (5.8 to 8.6)	7.0 (5.9 to 9.0)	6.9 (5.7 to 9.1)	6.7 (5.7 to 8.2)	6.8 (5.8 to 8.4)	7.2 (6.0 to 8.7)
Prior statin, <i>n</i> (%)	210 (6%)	43 (4%)	10 (6%)	97 (9%)	32 (10%)	28 (6%)
Vascular risk factors, <i>N</i> (%)						
Previous stroke	558 (19%)	184 (20%)	35 (21%)	197 (18%)	64 (20%)	78 (17%)
Previous TIA	258 (9%)	83 (9%)	10 (6%)	96 (9%)	28 (9%)	41 (9%)
Diabetes mellitus	685 (22%)	231 (24%)	42 (25%)	218 (19%)	71 (22%)	123 (25%)
Hypertension	1994 (66%)	609 (64%)	115 (69%)	731 (66%)	213 (65%)	326 (67%)
Previous myocardial infarction	390 (13%)	142 (15%)	16 (10%)	136 (12%)	46 (14%)	50 (10%)
Atrial fibrillation	841 (29%)	302 (33%)	43 (27%)	277 (27%)	78 (26%)	141 (31%)
Smoking status						
Non-smoker	322 (10%)	94 (10%)	10 (6%)	133 (12%)	37 (11%)	48 (10%)
Smoker	495 (16%)	147 (15%)	19 (11%)	191 (17%)	63 (19%)	75 (15%)
90 day outcomes, median (IQR)						
mRS	4 (3 to 6)	5 (4 to 6)	4 (2 to 5)	4 (2 to 5)	4 (2 to 6)	4 (3 to 6)
BI	25 (0 to 80)	5 (0 to 55)	55 (0 to 95)	50 (5 to 85)	30 (0 to 85)	10 (0 to 70)
NIHSS	11 (4 to 42)	17 (7 to 42)	7 (3 to 42)	8 (3 to 16)	11 (3 to 42)	13 (5 to 42)
90 day case fatality, <i>n</i> (%)	794 (26%)	353 (37%)	39 (23%)	157 (14%)	84 (26%)	161 (33%)

NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; TIA, transient ischemic attack; BI, Barthel Index.

TABLE 3 | Baseline characteristics and 90 day outcomes according to antibiotic class exposure in any infection.

	Lincosamides and tetracyclines	Cephalosporins, carbapenems and monobactams	Aminoglycosides	Fluoroquinolones	Penicillins	Penicillin plus β -lactamase inhibitors	Other*	Macrolides
Number of patients	180	815	165	930	315	873	670	142
Median (IQR) age (y)	74 (63 to 80)	73 (65 to 80)	73 (67 to 79)	74 (66 to 80)	75 (65 to 80)	74 (65 to 80)	75 (67 to 81)	71 (62 to 79)
Female sex, <i>n</i> (%)	73 (41%)	363 (45%)	59 (36%)	505 (54%)	158 (50%)	385 (44%)	384 (57%)	61 (43%)
Median (IQR) NIHSS	17 (12 to 20)	15 (11 to 19)	16 (12 to 19)	14 (11 to 19)	15 (11 to 19)	15 (11 to 19)	15 (11 to 19)	13 (9 to 18)
Median (IQR) time to first infection (d)	4 (2 to 8)	5 (2 to 8)	6 (3 to 12)	5 (3 to 10)	7 (4 to 17)	4 (2 to 7)	6 (3 to 15)	5 (2 to 11)
IV thrombolysis, <i>n</i> (%)	43 (24%)	187 (23%)	30 (18%)	267 (29%)	73 (23%)	248 (28%)	179 (27%)	36 (25%)
Mean (SD) pre-stroke mRS	1.2 (0.7)	1.2 (0.6)	1.4 (0.8)	1.1 (0.5)	1.5 (0.9)	1.1 (0.6)	1.4 (0.8)	1.3 (0.7)
Median (IQR) glucose (mmol/L)	7.4 (5.9 to 9.1)	6.8 (5.8 to 8.9)	7.3 (6.1 to 8.5)	6.8 (5.9 to 8.4)	6.7 (5.8 to 8.6)	7.2 (5.9 to 9.2)	6.7 (5.8 to 8.3)	6.5 (5.7 to 7.9)
Prior statin, <i>n</i> (%)	8 (4%)	62 (8%)	11 (7%)	66 (7%)	22 (7%)	58 (7%)	60 (9%)	4 (3%)
Vascular risk factors, <i>n</i> (%)								
Previous stroke	33 (19%)	146 (19%)	31 (19%)	156 (17%)	50 (17%)	149 (18%)	148 (23%)	28 (20%)
Previous TIA	15 (9%)	62 (8%)	13 (8%)	77 (9%)	22 (7%)	68 (8%)	59 (9%)	9 (6%)
Diabetes mellitus	49 (27%)	189 (23%)	42 (25%)	195 (21%)	68 (22%)	222 (25%)	155 (23%)	23 (16%)
Hypertension	108 (60%)	518 (65%)	117 (71%)	607 (66%)	195 (64%)	557 (65%)	460 (69%)	69 (49%)
Previous myocardial infarction	25 (14%)	98 (12%)	31 (19%)	113 (12%)	35 (11%)	104 (12%)	87 (13%)	17 (12%)
Atrial fibrillation	60 (35%)	216 (29%)	47 (30%)	243 (28%)	92 (32%)	234 (28%)	172 (28%)	34 (25%)
Smoking status								
Non-smoker	23 (13%)	107 (13%)	14 (8%)	121 (13%)	39 (12%)	51 (6%)	56 (8%)	10 (7%)
Smoker	31 (17%)	153 (19%)	28 (17%)	160 (17%)	61 (19%)	105 (12%)	140 (21%)	27 (19%)
90 day outcomes, median (IQR)								
mRS	5 (4 to 6)	4 (3 to 6)	5 (4 to 6)	4 (3 to 5)	4 (3 to 5)	4 (3 to 6)	4 (3 to 6)	3 (2 to 5)
BI	0 (0 to 45)	10 (0 to 65)	0 (0 to 45)	40 (0 to 85)	25 (0 to 75)	20 (0 to 75)	15 (0 to 70)	65 (0 to 95)
NIHSS	19 (8 to 42)	14 (6 to 42)	20 (8 to 42)	9 (3 to 36)	11 (4 to 42)	12 (5 to 42)	12 (4 to 42)	7.5 (3 to 42)
90 day case fatality, <i>n</i> (%)	69 (39%)	271 (33%)	64 (39%)	203 (22%)	63 (20%)	264 (31%)	180 (27%)	32 (23%)

*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides, and nitrofurans.

NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; TIA, transient ischemic attack; BI, Barthel Index.

in tracheobronchitis, 21% in urogenital infections and 33% in other infections.

In the primary analyses (Table 7, Figures 1, 2), treatment with macrolides (5% of any infections; 9% of pneumonias) was independently associated with more favorable mRS distribution for any infection [OR (95% CI) = 0.59 (0.42 to 0.83), $p = 0.004$] and for pneumonia [OR (95% CI) = 0.46 (0.29 to 0.73), $p = 0.001$]. By contrast, unfavorable mRS distribution was independently associated with treatment of any infection with carbapenems, cephalosporins or monobactams [35% of any infections; OR (95% CI) = 1.62 (1.33 to 1.97), $p < 0.001$], penicillin plus β -lactamase inhibitor [35% of any infections; OR (95% CI) = 1.26 (1.03

to 1.54), $p = 0.025$] or with aminoglycosides [7% of any infections; OR (95% CI) = 1.73 (1.22 to 2.46), $p = 0.002$] (Figure 1).

In secondary analyses, treatment with macrolides for any infection or pneumonia was also independently associated with more favorable BI and NIHSS (Tables 8, 9, Figures 1, 2). Treatment of any infection with carbapenems, cephalosporins or monobactams; penicillin plus β -lactamase inhibitor or with aminoglycosides was also independently associated with unfavorable BI and NIHSS (Figure 1).

A sensitivity analysis of the primary and secondary analyses included interaction terms between each antibiotic class and baseline stroke severity using the NIHSS score.

TABLE 4 | Baseline characteristics and 90 day outcomes according to antibiotic class exposure in pneumonia.

	Lincosamides and tetracyclines	Cephalosporins, carbapenems, and monobactams	Aminoglycosides	Fluoroquinolones	Penicillins	Penicillin plus β -lactamase inhibitors	Other*	Macrolides
Number of patients	120	403	78	254	115	395	224	83
Median (IQR) age (y)	75 (64 to 80)	73 (64 to 80)	72.5 (64 to 80)	75 (67 to 80)	76 (66 to 81)	75 (67 to 81)	75 (67.5 to 81)	70 (64 to 79)
Female sex, <i>n</i> (%)	48 (40%)	159 (39%)	24 (31%)	97 (38%)	44 (38%)	161 (41%)	93 (42%)	37 (45%)
Median (IQR) NIHSS	17 (12 to 20)	16 (12 to 19)	16.5 (13 to 20)	16 (13 to 20)	16 (13 to 18)	16 (12 to 20)	16 (11 to 19)	14 (10 to 18)
Median (IQR) time to first infection (d)	4 (2 to 7)	4 (2 to 7)	5 (3 to 8)	4 (2 to 7.5)	6 (3 to 15)	4 (2 to 7)	5 (3 to 9)	3.5 (1 to 7)
IV thrombolysis, <i>n</i> (%)	27 (23%)	96 (24%)	13 (17%)	87 (34%)	29 (25%)	131 (33%)	65 (29%)	19 (23%)
Mean (SD) pre-stroke mRS	1.3 (0.7)	1.2 (0.5)	1.4 (0.8)	1.1 (0.5)	1.4 (0.8)	1.2 (0.6)	1.3 (0.8)	1.2 (0.7)
Median (IQR) glucose (mmol/L)	7.4 (6 to 9.7)	6.8 (5.7 to 8.9)	7 (5.8 to 8.4)	6.8 (5.9 to 8.9)	6.7 (5.9 to 8.6)	7.3 (5.9 to 9.8)	6.7 (5.7 to 8.3)	6.4 (5.7 to 8.2)
Prior statin, <i>n</i> (%)	3 (3%)	26 (6%)	3 (4%)	12 (5%)	7 (6%)	18 (5%)	13 (6%)	1 (1%)
Vascular risk factors, <i>n</i> (%)								
Previous stroke	22 (19%)	78 (21%)	13 (18%)	43 (17%)	25 (22%)	67 (17%)	46 (21%)	18 (22%)
Previous TIA	9 (8%)	30 (8%)	9 (12%)	25 (10%)	11 (10%)	34 (9%)	12 (5%)	5 (6%)
Diabetes mellitus	28 (23%)	96 (24%)	18 (23%)	64 (25%)	23 (20%)	106 (27%)	54 (24%)	11 (13%)
Hypertension	64 (54%)	248 (63%)	53 (68%)	169 (67%)	76 (67%)	252 (65%)	152 (68%)	37 (45%)
Previous myocardial infarction	19 (15%)	57 (14%)	12 (15%)	36 (14%)	19 (17%)	56 (14%)	31 (13%)	10 (12%)
Atrial fibrillation	44 (39%)	119 (32%)	22 (29%)	72 (30%)	44 (40%)	122 (33%)	69 (34%)	20 (24%)
Smoking status								
Non-smoker	14 (12%)	57 (14%)	7 (9%)	33 (13%)	9 (8%)	31 (8%)	15 (7%)	6 (7%)
Smoker	21 (18%)	79 (20%)	13 (17%)	54 (21%)	23 (20%)	52 (13%)	48 (21%)	14 (17%)
90 Day outcomes, median (IQR)								
mRS	5 (4 to 6)	5 (4 to 6)	5 (4 to 6)	5 (4 to 6)	4 (4 to 6)	5 (4 to 6)	5 (4 to 6)	4 (2 to 6)
BI	0 (0 to 35)	5 (0 to 50)	0 (0 to 25)	5 (0 to 45)	5 (0 to 40)	5 (0 to 55)	0 (0 to 35)	60 (0 to 95)
NIHSS	19 (8 to 42)	18 (7.5 to 42)	42 (10 to 42)	16 (7 to 42)	16 (8 to 42)	16 (7 to 42)	19 (8 to 42)	8 (3 to 42)
90 day case fatality, <i>n</i> (%)	45 (38%)	151 (38%)	32 (41%)	90 (36%)	32 (28%)	144 (37%)	85 (38%)	22 (27%)

*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides, and nitrofurans.

NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; TIA, transient ischemic attack; BI, Barthel Index.

This was to examine whether any apparent association between antibiotic class and change in outcome could be due to an interaction with stroke severity. We did not find evidence of any interaction between any of the antibiotic classes and baseline stroke severity, including for macrolides (data not shown).

Forty-five percent of infections treated with macrolides were with macrolides alone. In the remainder, macrolides were most frequently combined with cephalosporins, fluoroquinolones or penicillin plus β -lactamase inhibitor. By contrast, 70% of infections treated with penicillin plus β -lactamase inhibitor were with monotherapy, the remainder were combined most

often with fluoroquinolones or cephalosporins. Fifty-nine percent of infections treated with cephalosporins were with monotherapy, the remainder used combination treatment most often with metronidazole, fluoroquinolones or penicillin plus β -lactamase inhibitor.

DISCUSSION

We found that treatment with macrolides was independently associated with a favorable clinical outcome in any infection or pneumonia complicating stroke. Macrolides were only used in a minority of post-stroke infections and were mainly used

TABLE 5 | Prevalence of antibiotic classes for infection categories expressed as % of total number of antibiotic prescriptions.

Number of patients	Any infection 2708	Pneumonia 958	Tracheobronchitis 170	Urogenital infection 1132	Other infection 330	Uncertain infection 490
Number of antibiotic prescriptions	5237	1862	233	1723	650	769
Antibiotic class, <i>n</i> (%)						
Lincosamides and tetracyclines						
Tetracyclines	33 (0.6%)	10 (0.5%)	9 (3.9%)	1 (<0.1%)	13 (2%)	0
Lincosamides	186 (3.6%)	124 (6.7%)	3 (1.3%)	10 (0.6%)	15 (2.3%)	34 (4.4%)
Cephalosporins, carbapenems, monobactams						
Cephalosporins	986 (18.8%)	436 (23.4%)	45 (19.3%)	216 (12.5%)	125 (19.2%)	164 (21.3%)
Carbapenems	90 (1.7%)	49 (2.6%)	2 (0.9%)	13 (0.8%)	18 (2.8%)	8 (1.0%)
Monobactams	11 (0.2%)	1 (<0.1%)	0	2 (0.1%)	6 (0.9%)	2 (0.3%)
Aminoglycosides	208 (4%)	82 (4.4%)	9 (3.9%)	33 (1.9%)	56 (8.6%)	28 (3.6%)
Fluoroquinolones	1129 (21.6%)	244 (13.1%)	50 (21.5%)	651 (37.8%)	66 (10.2%)	118 (15.3%)
Penicillins	433 (8.3%)	138 (7.4%)	15 (6.4%)	164 (9.5%)	64 (9.9%)	52 (6.8%)
Penicillin plus β -lactamase inhibitors	1082 (20.7%)	456 (24.5%)	80 (34.3%)	179 (10.4%)	83 (12.8%)	284 (36.9%)
Other						
Glycopeptides	184 (3.5%)	74 (4.0%)	1 (0.4%)	17 (1%)	67 (10.3%)	25 (3.3%)
Metronidazole	301 (5.7%)	151 (8.1%)	2 (0.9%)	24 (1.4%)	96 (14.8%)	28 (3.6%)
Nitrofurans	60 (1.1%)	0	0	58 (3.4%)	0 (0)	2 (0.3%)
Sulphonamides/folic acid inhibitors	372 (7.1%)	9 (0.5%)	2 (0.9%)	346 (20.1%)	8 (1.2%)	7 (0.9%)
Macrolides	162 (3.1%)	88 (4.7%)	15 (6.4%)	9 (0.5%)	33 (5.1%)	17 (2.2%)

TABLE 6 | Number of antibiotic agents prescribed for infection categories.

Number of patients	Any infection 2708	Pneumonia 958	Tracheobronchitis 170	Urogenital infection 1132	Other infection 330	Uncertain infection 490
NUMBER OF ANTIBIOTIC AGENTS PRESCRIBED, <i>n</i> (%)						
1	2184 (70.9%)	554 (57.8%)	136 (80.0%)	895 (79.1%)	221 (67.0%)	378 (77.0%)
2	669 (21.7%)	295 (30.8%)	30 (17.7%)	188 (16.6%)	72 (21.8%)	84 (17.1%)
3	165 (5.4%)	85 (8.9%)	2 (1.2%)	35 (3.1%)	21 (6.4%)	22 (4.5%)
4	49 (1.6%)	17 (1.8%)	2 (1.2%)	11 (1.0%)	12 (3.6%)	7 (1.4%)
5	11 (0.4%)	5 (0.5%)	0	2 (0.2%)	4 (1.2%)	0
6	3 (0.1%)	2 (0.2%)	0	1 (0.1)	0	0

as combination therapy with other antibiotics. By contrast, treatment with cephalosporins, carbapenems or monobactams; or penicillin plus β -lactamase inhibitors, was consistently associated with unfavorable outcome in any infection, but not pneumonia. These two classes were each used in the treatment of over one third of post-stroke infections, mainly as monotherapy. Aminoglycosides were also associated with unfavorable outcome when used to treat any infection but accounted for a small proportion of the antibiotic classes used. These associations were consistently observed with all three clinical outcome measures in the primary and secondary analyses.

Genito-urinary infections were marginally more frequent than pneumonia in our study. This is in keeping with a recent study using both clinician-diagnosed and expert panel-adjudicated diagnosis of urinary tract infection and

pneumonia (3) and estimates from meta-analysis of stroke studies (2, 24, 25). However, pneumonia is associated with substantial risk of death and disability compared to urinary tract infections (2) and is regarded as the major research and clinical priority amongst stroke-associated infections. Our data accord with this as only pneumonia, but not other infection sub-types, was independently associated with worse clinical outcomes.

Our retrospective study has several limitations which necessitate caution when interpreting the findings. First, choice of antibiotic class will have been influenced by study- and individual-level factors, leading to effect modification and confounding by indication. We were unable to include a trial-identifier in our analyses to account for non-specific differences in study populations. Perceived severity of infection will likely have been a determinant of choice of antibiotic

TABLE 7 | Multifactorial ordinal logistic regression for associations with unfavorable 90 day mRS.

	Pneumonia (n = 791 patients)			Any infection (n = 2254 patients)		
	OR	95% CI	p	OR	95% CI	p
Antibiotic class						
Lincosamides and tetracyclines	0.95	0.62 to 1.45	0.82	1.37	0.98 to 1.91	0.07
Cephalosporins, carbapenems, and monobactams	1.31	0.96 to 1.78	0.09	1.62	1.33 to 1.97	<0.001
Aminoglycosides	1.04	0.62 to 1.76	0.87	1.73	1.22 to 2.46	0.002
Fluoroquinolones	1.05	0.77 to 1.44	0.74	1.22	1.01 to 1.47	0.040
Penicillins	0.95	0.62 to 1.44	0.81	1.16	0.89 to 1.52	0.28
Penicillin plus β -lactamase inhibitor	0.94	0.69 to 1.28	0.68	1.26	1.03 to 1.54	0.025
Other*	1.30	0.72 to 2.35	0.38	1.48	1.21 to 1.82	<0.001
Macrolides	0.46	0.29 to 0.73	0.001	0.59	0.42 to 0.83	0.004
Sex						
Female	Ref			Ref		
Male	1.02	0.79 to 1.33	0.86	1.02	0.87 to 1.19	0.84
Increasing age (y)	1.05	1.04 to 1.06	<0.001	1.05	1.04 to 1.05	<0.001
Baseline NIHSS	1.11	1.08 to 1.15	<0.001	1.15	1.13 to 1.17	<0.001
Infection subtype						
Pneumonia				1.47	1.09 to 1.97	0.011
Tracheobronchitis				0.92	0.63 to 1.36	0.69
Urogenital				0.64	0.48 to 0.85	0.002
Other				0.77	0.57 to 1.02	0.097
Uncertain				1.17	0.86 to 1.58	0.31
Treated with IV alteplase						
No	Ref			Ref		
Yes	0.95	0.70 to 1.29	0.73	0.80	0.66 to 0.96	0.016
Prior statin						
No	Ref			Ref		
Yes	1.14	0.30 to 2.16	0.69	1.14	0.83 to 1.57	0.42
Unrecorded	1.71	0.96 to 3.02	0.07	1.62	1.18 to 2.23	0.003
Smoking status						
Non-smoker	Ref			Ref		
Smoker	1.29	0.67 to 2.16	0.69	1.21	0.83 to 1.57	0.42
Unrecorded	1.15	0.49 to 2.68	0.75	1.04	0.65 to 1.67	0.88
Region						
Australasia/ Africa	Ref			Ref		
Asia	0.85	0.39 to 1.85	0.68	1.14	0.68 to 1.92	0.62
Europe	0.85	0.41 to 1.77	0.66	1.10	0.67 to 1.79	0.72
America	0.92	0.44 to 1.96	0.84	1.03	0.62 to 1.69	0.91
Increasing year of study	0.97	0.90 to 1.04	0.41	1.00	0.96 to 1.04	0.88

*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides and nitrofurans.

mRS, modified Rankin Scale; OR, Odds ratio; CI, Confidence Interval; NIHSS, National Institutes of Health Stroke Scale; IV, intravenous.


class, along with availability of oral, enteral or parenteral routes, local antibiotic policy and allergy status. Bacterial species implicated in aspiration pneumonia have changed in recent years as anaerobes are less frequently isolated (26). Changing patterns of antimicrobial susceptibility may also have influenced regional and local prescribing. Plasma C-reactive

protein was not sufficiently available for the regression analyses, but may still have been used by treating clinicians to inform antibiotic choice. Second, details of route, dose and duration of treatment were not available and may also have influenced the findings. Third, the criteria used for diagnosis of infection were not available and will have varied between different units, leading to under- or over-diagnosis and therefore selection bias. There were also very limited microbiological data available, reflected by the need for an uncertain infection category, where infection was suspected (and antibiotics initiated) yet a definite site was not recorded. As there are no ubiquitous, validated criteria for diagnosing common post-stroke infections such as pneumonia, and positive microbiological data are infrequent (27), this reflects real-life practice. Finally, our categorization of antibiotic class required a balance between prevalence and mechanisms of action, to avoid over-fitting the regression models. We were therefore unable to further sub-divide antibiotic classes, such as creating a separate category for carbapenems and for monobactams, or by generation of drug (e.g., cephalosporins).

In randomized trials of prophylactic antibiotics in acute stroke, several classes of antibiotics commonly used for post-stroke infections, including cephalosporins, penicillin plus β -lactamase inhibitors and fluoroquinolones, did not appear to prevent pneumonia complicating stroke, even in patients selected at higher-risk (3, 5, 15–17). This raises the possibility that some antibiotics are not optimally effective against pneumonia complicating stroke (18). Whilst this may have contributed to our observations, the limitations of our study necessitate that such hypothesis-generation requires testing in appropriately designed studies.

Antibiotics used to treat post-stroke infections could influence clinical outcome by three main mechanisms. First, antimicrobial spectrum could explain differential outcomes between antibiotic classes. Stroke-associated pneumonia is predominantly associated with aerobic Gram-negative bacilli (e.g., *Klebsiella pneumoniae* and *Escherichia coli*) and Gram-positive cocci (e.g., *Staphylococcus spp.*) (27). Whilst the antimicrobial spectrum of β -lactam antibiotics varies, penicillin plus β -lactamase inhibitors and third generation cephalosporins are broadly comparable despite differences in coverage of *Pseudomonas spp.* By contrast, macrolides are mainly active against Gram-positive organisms (e.g., *Streptococcus pneumoniae*), with limited activity against Gram-negative organisms. It therefore seems unlikely that any beneficial effect of macrolide therapy for stroke-associated infections (including stroke-associated pneumonia) would be explained on the basis of anti-microbial spectrum. However, macrolides improve coverage of atypical organisms in community acquired pneumonia (CAP), and have synergistic effects combined with β lactam agents, which could be relevant in stroke-associated pneumonia (28). Indeed, macrolides reduced in-patient mortality rates in hospitalized, severe CAP when added to β -lactam antibiotics (29).


Second, several antibiotic classes have immuno-modulatory effects which could either facilitate host immune responses to



bacterial challenge, or limit excessive inflammation in the lung. Macrolides have a range of immuno-modulatory effects (30), suppressing innate responses and inducing Th1 to Th2 shift. In a mouse model of pneumococcal pneumonia, addition of azithromycin to ceftriaxone induced specific changes in immune-checkpoint ligands (e.g., up-regulation of CD86 and MHC II in neutrophils and CD11b⁺CD11c⁺ macrophages) and receptors (e.g., down-regulation of CTLA-4) in bronchoalveolar lavage

fluid, which may have contributed to the observed increased survival (31).

Third, peripherally administered antibiotics could have protective or deleterious effects on evolving cerebral infarction, reparative processes, or both, particularly as they are frequently prescribed within the first week after stroke onset. In experimental stroke, in the absence of infection, macrolides administered peripherally after middle cerebral artery occlusion



are consistently protective; reducing infarct volume, blood brain barrier damage, markers of oxidative stress, infiltration of circulating immune cells and early neurological deficit (12, 14, 32–34). By contrast, peripheral administration of third generation cephalosporins in experimental stroke has revealed conflicting findings in different studies (10, 35, 36). However, in humans, cerebrospinal-fluid penetration of macrolides and β -lactam antibiotics is generally poor, and highest for fluoroquinolones and metronidazole (37).

CONCLUSION

In this retrospective analysis, treatment of any infection or pneumonia within 2 weeks of stroke with macrolides was independently associated with a favorable clinical outcome. By contrast, treatment of any infection with cephalosporins, carbapenems or monobactams; or penicillin plus β -lactamase, was independently associated with unfavorable outcome. Although there is a risk of residual confounding and bias,

TABLE 8 | Multifactorial ordinal logistic regression for associations with worse 90 day BI.

	Pneumonia (n = 751 patients)			Any infection (n = 2124 patients)		
	OR	95% CI	p	OR	95% CI	p
Antibiotic class						
Lincosamides and tetracyclines	1.02	0.66 to 1.57	0.95	1.53	1.09 to 2.15	0.015
Cephalosporins, carbapenems and monobactams	1.36	0.99 to 1.87	0.05	1.70	1.39 to 2.07	<0.001
Aminoglycosides	1.09	0.63 to 1.88	0.75	1.69	1.17 to 2.44	0.005
Fluoroquinolones	1.11	0.81 to 1.53	0.54	1.27	1.04 to 1.55	0.02
Penicillins	1.05	0.66 to 1.67	0.84	1.19	0.90 to 1.57	0.23
Penicillin plus β-lactamase inhibitor	1.00	0.73 to 1.37	0.98	1.30	1.05 to 1.61	0.02
Other*	1.26	0.67 to 2.36	0.47	1.53	1.24 to 1.89	<0.001
Macrolides	0.38	0.24 to 0.61	<0.001	0.50	0.35 to 0.72	<0.001
Sex						
Female	Ref			Ref		
Male	1.02	0.78 to 1.33	0.91	1.03	0.88 to 1.21	0.73
Increasing age (y)	1.05	1.04 to 1.06	<0.001	1.05	1.04 to 1.06	<0.001
Baseline NIHSS	1.11	1.08 to 1.14	<0.001	1.14	1.12 to 1.16	<0.001
Infection subtype						
Pneumonia				1.52	1.12 to 2.07	0.007
Tracheobronchitis				0.79	0.53 to 1.17	0.24
Urogenital				0.65	0.49 to 0.88	0.005
Other				0.86	0.62 to 1.20	0.38
Uncertain				1.18	0.86 to 1.62	0.31
Treated with IV alteplase						
No	Ref					
Yes	0.85	0.62 to 1.16	0.31	0.70	0.58 to 0.84	<0.001
Prior statin						
No	Ref					
Yes	1.09	0.49 to 2.46	0.83	1.32	0.90 to 1.92	0.15
Unrecorded	1.38	0.78 to 2.47	0.27	1.17	0.84 to 1.61	0.35
Smoking status						
Non-smoker	Ref					
Smoker	1.06	0.56 to 2.01	0.85	0.81	0.55 to 1.19	0.29
Unrecorded	1.09	0.47 to 2.52	0.84	0.98	0.61 to 1.58	0.94
Region						
Australasia/Africa	Ref					
Asia	0.88	0.40 to 1.94	0.74	1.17	0.68 to 2.02	0.57
Europe	1.06	0.51 to 2.20	0.88	1.53	0.92 to 2.53	0.10
America	1.08	0.51 to 2.28	0.85	1.27	0.76 to 2.11	0.36
Increasing year of study	1.00	0.93 to 1.08	0.98	1.04	1.00 to 1.09	0.05

*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides and nitrofurans.

BI, Barthel Index; OR, Odds ratio; CI, Confidence Interval; NIHSS, National Institutes of Health Stroke Scale; IV, intravenous.

these data warrant further study in an appropriately designed prospective study or controlled trial evaluation.

DATA AVAILABILITY

The datasets used in the analyses for this manuscript were obtained from the Virtual International Stroke Trials Archive (VISTA)-Acute (www.virtualtrialsarchives.org/vista). Requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to VISTA-Acute at vista.acute@glasgow.ac.uk.

TABLE 9 | Multifactorial ordinal logistic regression for associations with worse 90 day NIHSS.

	Pneumonia (n = 781 patients)			Any infection (n = 2215 patients)		
	OR	95% CI	P	OR	95% CI	p
Antibiotic class						
Lincosamides and tetracyclines	0.96	0.63 to 1.46	0.86	1.33	0.96 to 1.85	0.09
Cephalosporins, carbapenems, and monobactams	1.26	0.93 to 1.70	0.14	1.56	1.28 to 1.90	<0.001
Aminoglycosides	1.09	0.65 to 1.85	0.74	1.81	1.27 to 2.58	0.001
Fluoroquinolones	1.01	0.74 to 1.38	0.95	1.18	0.98 to 1.43	0.09
Penicillins	1.06	0.68 to 1.66	0.79	1.12	0.86 to 1.46	0.40
Penicillin plus β-lactamase inhibitor	0.95	0.70 to 1.29	0.73	1.26	1.04 to 1.53	0.02
Other*	1.34	0.74 to 2.44	0.34	1.33	1.08 to 1.63	0.006
Macrolides	0.59	0.37 to 0.94	0.03	0.67	0.56 to 0.80	0.007
Sex						
Female	Ref			Ref		
Male	1.12	0.86 to 1.45	0.41	1.08	0.92 to 1.26	0.34
Increasing age (y)	1.04	1.02 to 1.05	<0.001	1.03	1.02 to 1.04	<0.001
Baseline NIHSS	1.14	1.11 to 1.18	<0.001	1.18	1.16 to 1.20	<0.001
Infection subtype						
Pneumonia				1.57	1.17 to 2.11	0.003
Tracheobronchitis				0.95	0.65 to 1.38	0.78
Urogenital				0.68	0.51 to 0.91	0.008
Other				0.84	0.61 to 1.14	0.27
Uncertain				1.15	0.85 to 1.56	0.37
Treated with IV alteplase						
No	Ref					
Yes	0.93	0.69 to 1.27	0.66	0.78	0.65 to 0.93	0.007
Prior statin						
No	Ref					
Yes	1.06	0.56 to 2.00	0.87	1.00	0.73 to 1.38	0.99
Unrecorded	1.51	0.86 to 2.64	0.15	1.24	0.91 to 1.69	0.18
Smoking status						
Non-smoker	Ref					
Smoker	1.17	0.63 to 2.20	0.62	1.08	0.74 to 1.56	0.70
Unrecorded	1.04	0.45 to 2.39	0.93	0.97	0.60 to 1.54	0.88
Region						
Australasia/Africa	Ref					
Asia	1.19	0.55 to 2.59	0.66	1.59	0.95 to 2.64	0.08
Europe	0.97	0.47 to 2.01	0.94	1.18	0.73 to 1.90	0.51
America	1.05	0.50 to 2.22	0.90	1.16	0.71 to 1.90	0.54
Increasing year of study	0.96	0.90 to 1.04	0.32	0.99	0.95 to 1.03	0.57

*Other includes sulphonamides/folic acid inhibitors, metronidazole, glycopeptides and nitrofurans.

OR, Odds ratio; CI, Confidence Interval; NIHSS, National Institutes of Health Stroke Scale; IV, intravenous.

ETHICS STATEMENT

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the VISTA-Acute Steering

Committee, as part of the Data Request Form submission process. Informed consent was not required as anonymized historical patient data from randomized trials were being used.

INFORMED CONSENT

Informed consent was not required as anonymized historical patient data from randomized trials were being used.

AUTHOR CONTRIBUTIONS

CS conceived the study and was involved in study design, data acquisition, analysis, interpretation, drafting the manuscript, final approval for submission. CH and AV were involved in study design, data acquisition, analysis, interpretation, drafting the manuscript, final approval for submission. AJ was involved in study design, data acquisition, analysis, interpretation, drafting the manuscript, final approval for submission. WW, PN, DvdB, LK, JM, MW, and AM were involved in study design, interpretation, drafting the manuscript, final approval for submission. All authors agree to be accountable for all aspects of the manuscript.

REFERENCES

1. Finlayson O, Kapral M, Hall R, Asllani E, Selchen D, Saposnik G, On behalf of the Investigators of the Registry of the Canadian Stroke Network. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. *Neurology*. (2011) 77:1338–45. doi: 10.1212/WNL.0b013e31823152b1
2. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. *BMC Neurol*. (2011) 11:110. doi: 10.1186/1471-2377-11-110
3. Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruijff ND, Bosboom HJ, et al. The preventative antibiotics in stroke study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. *Lancet*. (2015) 385:1519–26. doi: 10.1016/S0140-6736(14)62456-9
4. Harms H, Hoffman S, Malzahn U, Ohlraun S, Heuschmann P, Meisel A. Decision-making in the diagnosis and treatment of stroke-associated pneumonia. *J Neurol Neurosurg Psychiatry*. (2012) 83:1225–30. doi: 10.1136/jnnp-2012-302194
5. Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, et al, on behalf of the STROKE-INF Investigators. prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. *Lancet*. (2015) 386:1835–44. doi: 10.1016/S0140-6736(15)00126-9
6. Chamorro Á, Meisel A, Planas AM, Urrea X, van de Beek D, Veltkamp R. The immunology of acute stroke. *Nat Rev Neurol*. (2012) 8:401–10. doi: 10.1038/nrneurol.2012.98
7. Smith CJ, Lawrence CB, Rodriguez-Grande B, Kovacs KJ, Pradillo JM, Denes A. The immune system in stroke: clinical challenges and their translation to experimental research. *J Neuroimmune Pharmacol*. (2013) 8:867–87. doi: 10.1007/s11481-013-9469-1
8. Wang Z, Xue Y, Jiao H, Liu Y, Wang P. Doxycycline-mediated protective effect against focal cerebral ischemia–reperfusion injury through the modulation of tight junctions and PKC δ signaling in rats. *J Mol Neurosci*. (2012) 47:89–100. doi: 10.1007/s12031-011-9689-x

FUNDING

The Open Access Publication Fund of Charité—Universitätsmedizin Berlin and Professor Meisel as corresponding author will provide funding to cover the open access publication/article processing fee.

ACKNOWLEDGMENTS

We thank the VISTA-Acute Steering Committee for providing access to the data, and also thank Dr. Myzoon Ali, VISTA coordinator, for screening the VISTA-Acute repository. The VISTA Steering Committee gave approval for the final version to be submitted for publication.

Data from this manuscript were presented in part at the 4th European Stroke Organization Conference in Gothenburg on May 17th, 2018.

The VISTA-Acute Steering Committee

K. R. Lees (Chair), A. Alexandrov, P. M. Bath, E. Berge, E. Bluhmki, N. Bornstein, C. Chen, L. Claesson, S. M. Davis, G. Donnan, H. C. Diener, M. Fisher, M. Ginsberg, B. Gregson, J. Grotta, W. Hacke, M. G. Hennerici, M. Hommel, M. Kaste, P. Lyden, J. Marler, K. Muir, N. Venketasubramanian, R. Sacco, A. Shuaib, P. Teal, N. G. Wahlgren, S. Warach, and C. Weimar.

9. Fan X, Lo EH, Wang X. Effects of minocycline plus tPA combination therapy after focal embolic stroke in type 1 diabetic rats. *Stroke*. (2013) 44:745–52. doi: 10.1161/STROKEAHA.111.000309
10. Kim SY, Jones TA. The effects of ceftriaxone on skill learning and motor functional outcome after ischemic cortical damage in rats. *Restor Neurol Neurosci*. (2013) 31:87–97. doi: 10.3233/RNN-2012-120245
11. Yang Y, Salayandia VM, Thompson JF, Yang LY, Estrada EY, Yang Y. Attenuation of acute stroke injury in rat brain by minocycline promotes blood–brain barrier remodeling and alternative microglia/macrophage activation during recovery. *J Neuroinflamm*. (2015) 12:26. doi: 10.1186/s12974-015-0245-4
12. Amantea D, Certo M, Petrelli F, Tassorelli C, Micieli G, Corasaniti MT, et al. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype. *Exp Neurol*. (2016) 275:116–25. doi: 10.1016/j.expneurol.2015.10.012
13. Becker KJ, Zierath D, Kunze A, Fecteau L, Lee B, Skerrett S. The contribution of antibiotics, pneumonia and the immune response to stroke outcome. *J Neuroimmunol*. (2016) 295–296:68–74. doi: 10.1016/j.jneuroim.2016.04.005
14. Katayama Y, Inaba T, Nito C, Ueda M. Neuroprotective effects of erythromycin on ischemic injury following permanent focal cerebral ischemia in rats. *Neurol Res*. (2016) 38:275–84. doi: 10.1080/01616412.2016.1138662
15. Chamorro A, Horcajada JB, Obach V, Vargas M, Revilla M, Torres F, et al. The early systemic prophylaxis of infection after stroke study. a randomized clinical trial. *Stroke*. (2005) 36:1495–500. doi: 10.1161/01.STR.0000170644.15504.49
16. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. *PLoS ONE*. (2008) 3:e2158. doi: 10.1371/journal.pone.0002158
17. Schwarz S, Al-Shajlawi F, Sick C, Meairs S, Hennerici MG. Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after acute ischemic stroke. the mannheim infection in stroke study (MISS). *Stroke*. (2008) 39:1220–27. doi: 10.1161/STROKEAHA.107.499533

18. Meisel A, Smith CJ. Preventive antibiotics for stroke-associated pneumonia. *Nat Rev Neurol.* (2015) 11:672–3. doi: 10.1038/nrneurol.2015.220
19. Ni Chróinín D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Díez-Tejedor E, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. *Stroke.* (2013) 44:448–56. doi: 10.1161/STROKEAHA.112.668277
20. Yeh PS, Lin HJ, Chen PS, Lin SH, Wang WM, Yang CM, et al. Effect of statin treatment on three-month outcomes in patients with stroke-associated infection: a prospective cohort study. *Eur J Neurol.* (2012) 19:689–69. doi: 10.1111/j.1468-1331.2011.03608.x
21. Scheitz JF, Endres M, Heuschmann PU, Audebert HJ, Nolte CH. Reduced risk of poststroke pneumonia in thrombolysed stroke patients with continued statin treatment. *Int J Stroke.* (2015) 10:61–6. doi: 10.1111/j.1747-4949.2012.00864.x
22. Weeks DL, Greer CL, Willson MN. Statin medication use and nosocomial infection risk in the acute phase of stroke. *J Stroke Cerebrovasc Dis.* (2016) 25:2360–7. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.033
23. Yu Y, Zhu C, Liu C, Gao Y. Effect of prior atorvastatin treatment on the frequency of hospital acquired pneumonia and evolution of biomarkers in patients with acute ischemic stroke: A multicenter prospective study. *Biomed Res Int.* (2017) 2017:5642704. doi: 10.1155/2017/5642704
24. Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, Di Napoli M, et al. How is pneumonia diagnosed in clinical stroke research? a systematic review and meta-analysis. *Stroke.* (2015) 46:1202–9. doi: 10.1161/STROKEAHA.114.007843
25. Yan T, Liu C, Li Y, Xiao W, Li Y, Wang S. Prevalence and predictive factors of urinary tract infection among patients with stroke: a meta-analysis. *Am J Infect Control.* (2018) 46:402–9. doi: 10.1016/j.ajic.2017.10.001
26. Mandell LA, Niederman MS. Aspiration pneumonia. *N Engl J Med.* (2019) 380:651–3 doi: 10.1056/NEJMra1714562
27. Kishore AK, Vail A, Jeans AR, Chamorro A, Di Napoli M, Kalra L, et al. Microbiological etiologies of pneumonia complicating stroke: a systematic review. *Stroke.* (2018) 49:1602–09. doi: 10.1161/STROKEAHA.117.020250
28. Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R. Beneficial effect of adjunctive azithromycin in treatment of mucoid *Pseudomonas aeruginosa* pneumonia in the murine model. *Antimicrob Agents Chemother.* (1999) 43:3033–35. doi: 10.1128/AAC.43.12.3033
29. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. *Respirology.* (2016) 21:1193–200. doi: 10.1111/resp.12835
30. Sadarangani SP, Estes LL, Steckelberg JM. Non-anti-infective effects of antimicrobials and their clinical applications: a review. *Mayo Clinic Proc.* (2015) 90:109–27. doi: 10.1016/j.mayocp.2014.09.006
31. Yoshioka D, Kajiwara C, Ishii Y, Umeki K, Hiramatsu K, Kadota J, et al. Efficacy of β -lactam-plus-macrolide combination therapy in a mouse model of lethal pneumococcal pneumonia. *Antimicrob Agents Chemother.* (2016) 60:6146–54. doi: 10.1128/AAC.01024-16
32. Amantea D, Certo M, Petrelli F, Bagetta G. Neuroprotective properties of a macrolide antibiotic in a mouse model of middle cerebral artery occlusion: characterization of the immunomodulatory effects and validation of the efficacy of intravenous administration. *Assay Drug Dev Technol.* (2016) 14:298–307. doi: 10.1089/adt.2016.728
33. Katayama Y, Inaba T, Nito C, Suda S, Ueda M. Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. *Life Sci.* (2017) 168:7–15. doi: 10.1016/j.lfs.2016.11.004
34. Petrelli F, Muzzi M, Chiarugi A, Bagetta G, Amantea D. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice. *Eur J Pharmacol.* (2016) 791:518–22. doi: 10.1016/j.ejphar.2016.09.030
35. Thöne-Reineke C, Neumann C, Namsolleck P, Schmerbach K, Krikov M, Scheffé JH, et al. The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. *J Hypertens.* (2008) 26:2426–35. doi: 10.1097/HJH.0b013e328313e403
36. Zierath D, Kunze A, Fecteau L, Becker K. Effect of antibiotic class on stroke outcome. *Stroke.* (2015) 46:2287–92. doi: 10.1161/STROKEAHA.115.008663
37. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infection. *Clin Microbiol Rev.* (2010) 23:858–83. doi: 10.1128/CMR.00007-10

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Smith, Heal, Vail, Jeans, Westendorp, Nederkoorn, van de Beek, Kalra, Montaner, Woodhead and Meisel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.